Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MediGene AG    MDG1   DE000A1X3W00

MEDIGENE AG

(MDG1)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Medigene : announces change in executive leadership team

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/03/2018 | 05:03am EDT

Planegg - Medigene AG (FSE: MDG1, Frankfurt, Prime Standard, TecDAX), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer announced today that the Chief Financial Officer (CFO), Dr. Thomas Taapken, will leave the Company for personal reasons and will resign from his CFO position effective August 31, 2018.

His departure is not based on any disagreement with the Company's accounting principles or practices, internal controls, financial statement disclosures or research and development pipeline.

The members of the executive management team and the Company's finance team will assume the duties and responsibilities of the CFO office on an interim basis while the Company undertakes a search for its next CFO. In order to ensure a smooth transition, Dr. Taapken will continue to advise the Company as a consultant to the executive management board until the end of the year.

Dr. Taapken has served as the Company's CFO since the beginning of 2017, during which time the Company completed two successful capital increases with broad participation from international investors. Prof. Horst Domdey, the Chairman of the Supervisory Board of Medigene AG, stated: 'On behalf of the Supervisory Board I want to thank Thomas for his significant contributions to Medigene as CFO.' Prof. Dr. Dolores J. Schendel, Chief Executive Officer of Medigene AG added: 'Thomas was highly committed to executing on the Company's corporate and financial strategy. Colleagues and employees owe him a great deal of respect and gratitude for his contributions. We wish Thomas all the best in his future endeavors.'

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene focuses on the development of personalized T cell-based therapies, with projects currently in preclinical and clinical development.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene and Veregen are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact:

Tel: +49 - 89 - 20 00 33 - 33 01

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIGENE AG
06/18MEDIGENE : Interim analysis from ongoing Phase I/II clinical trial with DC vacci..
AQ
06/17MEDIGENE : Interim analysis from ongoing Phase I/II clinical trial with DC vacci..
PU
05/27MEDIGENE : presented preclinical date on different TCR candidates at CIMT
AQ
05/23MEDIGENE : announces clinical trial agreement for HA-1 TCR immunotherapy MDG1021..
AQ
05/23MEDIGENE : reports on Annual General Meeting 2019
AQ
05/20MEDIGENE : to present interim data analysis from Phase I/II DC-Vaccine trial at ..
AQ
05/15MEDIGENE : reports financial and business results for the first three months of ..
AQ
05/09MEDIGENE : participates at upcoming conferences
AQ
05/02MEDIGENE : presented data on favorable safety pattern of PRAME-specific TCR on n..
PU
04/08MEDIGENE : sells remaining rights and inventories of Veregen® to Aresus Pharma
PU
More news
Financials (EUR)
Sales 2019 9,49 M
EBIT 2019 -27,7 M
Net income 2019 -27,8 M
Finance 2019 40,6 M
Yield 2019 -
P/E ratio 2019 -5,82x
P/E ratio 2020 -5,74x
EV / Sales2019 12,7x
EV / Sales2020 10,6x
Capitalization 161 M
Chart MEDIGENE AG
Duration : Period :
MediGene AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIGENE AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 13,48  €
Last Close Price 6,56  €
Spread / Highest target 162%
Spread / Average Target 105%
Spread / Lowest Target 37,2%
EPS Revisions
Managers
NameTitle
Dolores J. Schendel Chief Executive & Scientific Officer
Horst Domdey Chairman-Supervisory Board
Kai Pinkernell Chief Medical Officer & Senior Vice President
Yi Ta Li Member-Supervisory Board
Antoinette Hiebeler-Hasner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MEDIGENE AG-11.92%179
IQVIA HOLDINGS INC34.16%30 740
LONZA GROUP33.10%25 623
CELLTRION, INC.--.--%20 071
INCYTE CORPORATION26.66%17 271
EXACT SCIENCES CORPORATION82.06%14 835